Skip to main content
  • 217 Accesses

Abstract

Adverse reactions caused by drugs can be divided into two main groups, type A and type B reactions. Type A reactions represent nearly 80 %–85 % of these side effects and are caused by predictable pharmacological actions of the drug, while type B reactions develop on the basis of individual predisposition (idiosyncratic reactions, immune-mediated and nonimmune-mediated hypersensitivity reactions) and account for 15 %–20 % of adverse effects. The skin is the organ most commonly, but not exclusively, affected in drug hypersensitivity reactions both in the immune-mediated (allergic) and in the nonimmune-mediated (pseudoallergic) forms; these reactions are observed in 2 %–3 % of hospitalised patients. Immune-mediated drug hypersensitivity reactions comprise a heterogeneous group of diseases which can be classified according to Gell and Coombs (antibody-mediated drug hypersensitivity reactions: type I, IgE; type II and III, IgG; and type IV, T cell mediated). After better understanding of T-cell functions and discovery of subgroups, the late type IV reaction has been further subdivided in the revised form of Gell and Coombs classification (type IVa, T helper 1; type IVb, T helper 2; type IVc, T cytotoxic mediated and type IVd). Nonimmune-mediated hypersensitivity reactions are the so-called pseudoallergic reactions, which usually imitate IgE-mediated reactions with wheal and oedema formation, but sometimes anaphylaxis can also develop. These pseudoallergic reactions tend to arise less rapidly than true IgE-mediated allergies, they require higher doses of the drugs and neither IgE nor T-cell reactions can be demonstrated later. Non-specific histamine release, arachidonic acid pathway activation, bradykinin pathway alteration and complement activation can be detected in the background. Nonsteroidal anti-inflammatory drugs (NSAIDs), plasma expanders and radiocontrast media are the most common causes of pseudoallergic reactions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AGEP:

Acute generalised exanthematous pustulosis

DiHS:

Drug-induced hypersensitivity syndrome

DRESS:

Drug reaction with eosinophilia and systemic symptoms

HSS:

Hypersensitivity syndrome

LTT:

Lymphoblast transformation test

MDE:

Maculopapular drug eruption

NSAIDs:

Nonsteroidal anti-inflammatory drugs

SJS:

Stevens-Johnson syndrome

SSSS:

Staphylococcus scalded skin syndrome

TEN:

Toxic epidermal necrolysis

Reference

  • Kardaun SH, Sidoroff A, Valeyrie-Allanore, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609–11.

    Article  CAS  Google Scholar 

Further Reading

  • Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. A prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139:33–6.

    Article  CAS  Google Scholar 

  • Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149–53.

    Article  CAS  Google Scholar 

  • Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.

    Article  Google Scholar 

  • Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87:144–8.

    Article  CAS  Google Scholar 

  • Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7(2):142–60.

    PubMed  Google Scholar 

  • Pichler WJ, editor. Drug hypersensitivity. Basel: Karger; 2007.

    Google Scholar 

  • Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68(9):​1781–90.

    PubMed  Google Scholar 

  • Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209(2):123–9.

    Article  CAS  Google Scholar 

  • Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mochenhaupt M. Effects of treatment on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol. 2008;58(1):33–40.

    Article  Google Scholar 

  • Sidoroff A, Halevy S, Bouwes Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) – a clinical reaction pattern. J Cutan Pathol. 2001;28:113–9.

    Article  CAS  Google Scholar 

  • Verma R, Vasudevan B, Pragasam V. Severe cutaneous adverse drug reactions. Med J Armed Forces India. 2013;69(4):375–83.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrea Szegedi .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Szegedi, A., Remenyik, E. (2015). Drug Hypersensitivity Reactions. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D’Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45139-7_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45139-7_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45138-0

  • Online ISBN: 978-3-662-45139-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics